Up and down with PARs in vivo

Masakazu Fujiwara; Mohammad Ghazizadeh; Oichi Kawanami

doi:10.1055/s-0037-1613496

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2003; 90(05): 772-773
DOI: 10.1055/s-0037-1613496

Editorial Focus

Schattauer GmbH

Up and down with PARs in vivo

Masakazu Fujiwara

¹Department of Molecular Pathology, Institute of Gerontology, Graduate School of Medicine, Nippon Medical School, Kawasaki, Kanagawa, Japan

,

Mohammad Ghazizadeh

¹Department of Molecular Pathology, Institute of Gerontology, Graduate School of Medicine, Nippon Medical School, Kawasaki, Kanagawa, Japan

,

Oichi Kawanami

¹Department of Molecular Pathology, Institute of Gerontology, Graduate School of Medicine, Nippon Medical School, Kawasaki, Kanagawa, Japan

References
1 Davey MG, Luscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1967; 216 (118) 857-8.
2 Macfarlane SR, Seatter MJ, Kanke T. et al Proteinase-activated receptors. Pharmacol Rev 2001; 53 (02) 245-82.
3 Vu TK, Hung DT, Wheaton I V. et al Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64 (06) 1057-68.
4 Andersen H, Greenberg DL, Fujikawa K. et al Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A 1999; 96 (20) 11189-93.
5 Hein L, Ishii K, Coughlin SR. et al Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem 1994; 269 (44) 27719-26.
6 Woolkalis MJ, DeMelfi Jr. TM, Blanchard N. et al Regulation of thrombin receptors on human umbilical vein endothelial cells. J Biol Chem 1995; 270 (17) 9868-75.
7 Trejo J, Coughlin SR. The cytoplasmic tails of protease-activated receptor-1 and substan-ce P receptor specify sorting to lysosomes versus recycling. J Biol Chem 1999; 274 (04) 2216-24.
8 Hollenstein U, Homoncik M, Knobl P. et al Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. Clin Pharmacol Ther 2002; 71 (05) 368-74.
9 Stohlawetz P, Folman CC, von dem Borne AE. et al Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 1999; 81 (04) 613-7.
10 Dupont A, Fontana P, Bachelot-Loza C. et al An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003; 101 (05) 1833-40.
11 Hoxie JA, Ahuja M, Belmonte E. et al Inter-nalization and recycling of activated throm-bin receptors. J Biol Chem 1993; 268 (18) 13756-63.
12 Covic L, Singh C, Smith H. et al Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost 2002; 87 (04) 722-7.
13 Vogel CN, Kingdon HS, Lundblad RL. Correlation of in vivo and in vitro inhibition of thrombin by plasma inhibitors. J Lab Clin Med 1979; 93 (04) 661-73.
14 Zoldhelyi P, Bichler J, Owen WG. et al Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90 (06) 2671-8.